Sun Pharmaceutical Industries Ltd - Stock Valuation and Financial Performance

BSE: 524715 | NSE: SUNPHARMA | Pharmaceuticals & Drugs | Large Cap

Sun Pharma Inds. Share Price

1,622.30 14.20 0.88%
as on 28-Mar'24 15:00

DeciZen - make an informed investing decision on Sun Pharma Inds.

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat overvalued

3. Price Trend

Sun Pharmaceutical Industries stock performance -

mw4me loader
P/E Ratio (CD):
43.32
Market Cap:
3,85,837.1 Cr.
52-wk low:
922.6
52-wk high:
1,627

Is Sun Pharmaceutical Industries Ltd an attractive stock to invest in?

1. Is Sun Pharmaceutical Industries Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sun Pharmaceutical Industries Ltd is a good quality company.

2. Is Sun Pharmaceutical Industries Ltd undervalued or overvalued?

The key valuation ratios of Sun Pharmaceutical Industries Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

3. Is Sun Pharmaceutical Industries Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Sun Pharmaceutical Industries Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of Sun Pharma Inds.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Sun Pharmaceutical Industries Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 24.4%16.7%13.7%14.5%6%7.4%7.3%10.8%12.7%15.2%-
Value Creation
Index
1.20.50.20.3-0.5-0.3-0.40.00.10.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 16,08027,39228,10931,30826,41629,06632,83833,49838,65443,88646,671
Sales YoY Gr.-70.3%2.6%11.4%-15.6%10%13%2%15.4%13.5%-
Adj EPS 23.422.522.127.811.315.116.424.527.436.737.1
YoY Gr.--3.8%-1.8%25.9%-59.3%33.4%8.6%49.8%11.9%33.7%-
BVPS (₹) 89.4123.5137152.7159.7172.6188.7193.7200.1233.4260.1
Adj Net
Profit
4,8364,6535,3116,6642,7123,6163,9255,8826,5798,7978,906
Cash Flow from Ops. 3,9595,6166,6867,0823,9072,1966,5556,1708,9854,959-
Debt/CF from Ops. 0.71.61.31.42.74.81.30.60.11.3-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 11.8%10.7%10.2%13.5%
Adj EPS 5.1%26.5%30.9%33.7%
BVPS11.3%7.9%7.4%16.6%
Share Price 11.2% 27.8% 40.3% 64.8%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
28.921.118.119.17.29.19.112.813.916.915.1
Op. Profit
Mgn %
44.729.230.83121.122.121.325.326.526.827.3
Net Profit
Mgn %
34.720.522.924.112.114.313.215.717.420.219.1
Debt to
Equity
0.10.40.30.30.30.30.20.100.1-
Working Cap
Days
192189242239163154148146136130157
Cash Conv.
Cycle
6254838517274849444087

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 15.00%

Sales growth is growing at healthy rate in last 3 years 10.15%

Net Profit is growing at healthy rate in last 3 years 30.86%

Sales growth is good in last 4 quarters at 11.39%

No data to display

Latest Financials - Sun Pharmaceutical Industries Ltd.

Standalone Consolidated
TTM EPS (₹) 4 37.1
TTM Sales (₹ Cr.) 20,107 46,671
BVPS (₹.) 103.2 260.1
Reserves (₹ Cr.) 24,529 62,154
P/BV 15.58 6.18
PE 397.87 43.32
From the Market
52 Week Low / High (₹) 922.55 / 1627.00
All Time Low / High (₹) 1.65 / 1627.00
Market Cap (₹ Cr.) 3,85,837
Equity (₹ Cr.) 239.9
Face Value (₹) 1
Industry PE 47.8

Management X-Ray of Sun Pharma Inds.:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *6.524.795.574.042.531.921.782.292.442.44
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Sun Pharma Inds.

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales16,08027,39228,10931,30826,41629,06632,83833,49838,65443,886
Operating Expenses 9,08119,54319,95021,62620,88122,79225,86325,03028,77332,424
Manufacturing Costs1,7451,9223,7543,8824,0183,9793,9284,0822,5832,767
Material Costs2,7786,7336,1708,1647,3527,8699,2308,69010,35210,662
Employee Cost 1,7304,5034,2044,3124,7085,2985,7046,1267,3018,296
Other Costs 2,8286,3855,8225,2684,8035,6467,0026,1328,53710,699
Operating Profit 7,0007,8498,1589,6825,5356,2746,9748,4689,88211,461
Operating Profit Margin (%) 43.5%28.7%29.0%30.9%21.0%21.6%21.2%25.3%25.6%26.1%
Other Income 5525666581,0309121,0596528591,437820
Interest 44579523400518555303141127172
Depreciation 4091,1951,0381,2651,5001,7532,0532,0802,1442,529
Exceptional Items -2,517-238-6850-951-1,214-261-4,306-4,567-171
Profit Before Tax 4,5816,4036,5719,0483,4793,8105,0102,7994,4819,408
Tax 7029159141,2129116018235151,076848
Profit After Tax 3,8795,4885,6577,8362,5683,2094,1872,2853,4068,561
PAT Margin (%) 24.1%20.0%20.1%25.0%9.7%11.0%12.8%6.8%8.8%19.5%
Adjusted EPS (₹)15.221.918.929.08.711.115.712.113.635.3
Dividend Payout Ratio (%)10%14%5%12%23%25%25%62%73%33%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 18,52525,58232,97736,63738,31441,40945,26446,46348,01155,995
Share Capital 207207241240240240240240240240
Reserves 18,31825,37432,73636,39738,07441,16945,02546,22347,77155,755
Minority Interest1921285140853791388433143860301730553320
Debt2,4897,5968,3168,0919,7529,8937,5783,3436985,958
Long Term Debt491,3683,1101,4361,7721,5232,0298982300
Short Term Debt2,4406,2285,2066,6557,9808,3715,5492,4454695,958
Trade Payables1,3283,2873,5834,3954,7664,1483,5843,9744,4905,682
Others Liabilities 3,9217,6563,4206,0035,3933,3754,7917,31410,7046,624
Total Liabilities 28,18446,97252,38158,91762,10962,13965,07764,11066,95877,579

Fixed Assets

Gross Block10,48520,40722,18024,46626,94931,68735,11635,57938,70743,455
Accumulated Depreciation3,6687,7246,3086,7918,0969,85112,26914,02616,04219,035
Net Fixed Assets6,81712,68215,87217,67518,85321,83722,84721,55322,66524,420
CWIP 8422,0392,1752,8012,4651,4111,2201,5671,2874,973
Investments 2,7862,7161,8301,1927,1437,90310,1439,61212,84914,830
Inventories3,1235,6686,4236,8336,8817,8867,8758,9978,92510,513
Trade Receivables2,2005,1066,7767,2037,8158,8849,4219,06110,48511,439
Cash Equivalents 7,59010,99813,18215,1419,9297,2766,4886,4465,0335,770
Others Assets4,8267,7626,1248,0739,0236,9437,0836,8745,7155,634
Total Assets 28,18446,97252,38158,91762,10962,13965,07764,11066,95877,579

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 3,9595,6166,6867,0823,9072,1966,5556,1708,9854,959
PBT 4,5816,4036,5719,0483,4793,8105,0102,7994,4819,408
Adjustment -407741,8575011,3821,9691,9931,8101,9752,723
Changes in Working Capital 207180247-409-212-269689925641559-5662
Tax Paid -789-1,740-1,988-2,057-742-886-1,346-1,003969-1,510
Cash Flow From Investing Activity -2,367-2,866-4,372-4,222-3,371-681-2,589536-5,725-7,944
Capex -897-2,300-3,333-3,590-1,894-3,162-1,450-1,073-1,434-2,065
Net Investments -1,134-324-410-873-6771,752-1,7021,373-3,791-1,644
Others -336-242-629242-800729563236-499-4,235
Cash Flow From Financing Activity 507-1,187-1,889-2,285-1,539-2,731-5,715-5,980-5,1932,376
Net Proceeds from Shares 07592100000
Net Proceeds from Borrowing 0000000000
Interest Paid -23-350-301-334-477-461-272-144-73-99
Dividend Paid -518-310-724-243-813-1,326-1,399-1,586-2,159-2,519
Others 1,047-601-872-1,711-250-945-4,044-4,250-2,9614,994
Net Cash Flow 2,0991,563426575-1,003-1,215-1,749726-1,934-608
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)23.1524.8919.3222.516.858.059.664.987.2116.46
ROCE (%)25.4625.0618.6421.488.48.6810.075.669.2817.24
Asset Turnover Ratio0.680.740.570.570.850.910.930.951.031.03
PAT to CFO Conversion(x)1.021.021.180.91.520.681.572.72.640.58
Working Capital Days
Receivable Days52487681545456555354
Inventory Days64587777494848504948
Payable Days156125203178227207153159149174

Sun Pharmaceutical Industries Ltd Stock News

Sun Pharmaceutical Industries Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Sun Pharma Inds. on 28-Mar-2024 15:00 is ₹1,622.3.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 15:00 the market cap of Sun Pharma Inds. stood at ₹3,85,837.1.
The latest P/E ratio of Sun Pharma Inds. as of 28-Mar-2024 15:00 is 397.9.
The latest P/B ratio of Sun Pharma Inds. as of 28-Mar-2024 15:00 is 15.58.
The 52-week high of Sun Pharma Inds. is ₹1,627 and the 52-week low is ₹922.5.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sun Pharma Inds. is ₹20,107 ( Cr.) .

About Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries established in 1983 with five psychiatry products and a two person marketing team. Sun Pharma is the fifth largest specialty generic pharmaceutical company in the world. It provide high-quality, affordable medicines trusted by healthcare professionals and patients in many countries worldwide. Sun Pharma is also India’s largest and pharmaceutical company. Its global presence is supported by several manufacturing facilities across few continents. In the US market which contributes a significant share of its revenues, the company is the leader in the generic dermatology segment. It has strong capabilities in developing generic and complex products with a robust pipeline of many ANDAs, including high value First-to-File (FTF) opportunities. It has an established presence in Europe and key high-growth Emerging Markets (EM) like Russia, Romania, South Africa, Brazil and Malaysia. The company’s primary focus is to in-license generic and differentiated generic products that are close to commercialization or in advanced stage of development for North America, Western Europe and Japan markets.

The company is market leader in India and it is interested in partnerships for late stage and/or marketed opportunities complementary to its commercial footprint or expansion within its core areas of focus in India. These include CNS disorders, Cardiology, Diabetes and Metabolic disorders, Gastroenterology, Ophthalmology, Oncology, Pain, Rheumatology, Allergy, Asthma and Inflammation and Gynecology. Its focus is for NCEs, NBEs, NDDS based differentiated products, Biosimilars, Proprietary Technology Barrier Products which provide it the first mover advantage in India. The company’s leadership position in India allows it to offer significant value to innovator companies who want to partner with a dynamic and leading company, capable of successfully marketing its assets and willing to give the right priority to in-licensed or partnered projects.

Business area of the company

The company is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in many countries across the world, at affordable prices.

Products

  • Formulations
  • Active Pharmaceutical Ingredients - Crams
  • OTC

Awards

  • 2005:  Dilip Shanghvi is named Entrepreneur of the Year (Healthcare and Life Science) Ernst & Young.
  • 2007: Dilip Shanghvi is recognised as First Generation Entrepreneur of the Year CNBC-TV18.
  • 2007: Dilip Shanghvi wins Pharmaceutical Companies IMC Juran Quality Medal IMC Ramkrishna Bajaj National Quality Award Trust.
  • 2008: Sun Pharma wins Outstanding Exporter of the Year: Pharmaceuticals, Healthcare and Lifesciences Award CNBC TV 18:The International Trade Awards.
  • 2008: Sun Pharma receives Business Leadership Award NDTV Profit.
  • 2008: Dilip Shanghvi is named CEO of the Year Business Standard.
  • 2008: Dilip Shanghvi is honoured with Entrepreneur of the Year Award The Economic Times.
  • 2009: Sudhir V. Valia is named Best CFO in Pharma and Healthcare CNBC-TV18 CFO Awards.
  • 2009: Sun Pharma receives Rolta Corporate Award: Pharmaceuticals Dun & Bradstreet.
  • 2010: Dilip Shanghvi receives Entrepreneur of the Year Award Ernst & Young.
  • 2010: Sun Pharma receives Business Leadership of the Year Award NDTV PROFIT.
  • 2011: Dilip Shanghvi is recognised as World Entrepreneur of the Year Ernst & Young.
  • 2011: Dilip Shanghvi is honoured with Businessman of the Year Award Business India.
  • 2011: Dilip Shanghvi is named Indian of the Year (Business) CNN IBN.
  • 2011: Sudhir V. Valia is named Best CFO in Pharma and Healthcare CNBC-TV18 CFO Awards.
  • 2011: Sun Pharma is hailed as the Pharmaceutical Company of the Year Frost & Sullivan India Healthcare Excellence Awards.
  • 2012: Sun Pharma is named Most Outstanding Company of the Year CNBC-TV18 India Business Leader Awards.
  • 2012: Sun Pharma is listed among The World’s 100 Most Innovative Companies Forbes.
  • 2012: Sun Pharma is listed in Asia's Fab 50 Companies Forbes.
  • 2012: Sun Pharma wins Business Leadership of the Year - Pharmaceutical Award NDTV Profit.
  • 2013: Uday Baldota receives Best CFO in Pharma and Healthcare Award CNBC TV-18 CFO Awards.
  • 2013: Sun Pharma is named Company of the Year The Economic Times.
  • 2013: Sun Pharma is named Company of the Year Business Standard.
  • 2013: Sun Pharma is listed among Asia's Fab 50 Companies Forbes.
  • 2014: Dilip Shanghvi receives Entrepreneur of the Year Award Forbes Magazine.
  • 2014: Sun Pharma receives Cardiovascular Pharmaceutical Company of the Year Award Frost & Sullivan India Healthcare Excellence Awards.
  • 2014: Dilip Shanghvi receives Business Leader of the Year Award The Economic Times.
  • 2014: Sun Pharma is listed among The World’s 100 Most Innovative Companies Forbes.
  • 2014: Dilip Shanghvi receives JRD TATA Corporate Leadership Award All India Management Association.
  • 2015: Dilip Shanghvi receives Business Leader of the Year Award NDTV.
  • 2015: Sun Pharma receives Excellence in CSR Award “India Pharma Awards - 2015” instituted by UBM-India.
  • 2015: Sun Pharma receives India Pharma Research & Development Award 2015 Ministry of Chemicals & Fertilizers, Government of India.
  • 2016: Sun Pharmaceutical Industries Inc. receives DIANA (Distribution Industry Award for Notable Achievements) Award Healthcare Distribution Alliance, USA.
  • 2016: Dilip Shanghvi receives Padma Shri Award Government of India.
  • 2016: Sun Pharma receives Community Care Award ASSOCHAM (Associated Chambers of Commerce).
  • 2017: Dilip Shanghvi receives Entrepreneur of the Year Award All India Management Association (AIMA).
  • 2018: Dilip Shanghvi receives Lifetime Outstanding Achievement Award Indore Management Association (IMA).
  • 2018: Sun Pharma receives Outstanding Contribution in CSR Federation of Gujarat Industries.
  • 2018: Sun Pharma receives Best CSR Practices The Economic Times (ET).

Milestones

Establishment & Growth

  • 1983: The Company established with five psychiatry products and a two person marketing team
  • 1994: The Company lunches IPO
  • 1996: The Company expands sales network across 24 countries.
  • 2007: The Company demerges Sun Pharma Advanced Research Company (SPARC) into a separate entity becoming the first pure research company to be listed on India Stock Exchanges.
  • 2013: Ranbaxy acquisition catapults Sun Pharma to world’s 5th largest specialty generic pharmaceutical company.

Acquisitions & Alliances

  • 1996: The Company acquires API plant from Knoll Pharma at Ahmednagar, Maharashtra, India.
  • 1997: The Company purchases equity stakes in TDPL and MJ Pharma.
  • 1997: The Company’s first international acquisition of Caraco Pharmaceutical Laboratories, USA.
  • 1999: The Company acquires Milmet Labs and Gujrat Lyka Organics, India.
  • 2000: The Company acquires Pradeep Drug Company, India.
  • 2004: The Company acquires Phlox Pharma (India) and niche brands from Women’s First Healthcare (US).
  • 2005: The Company completes buyout of manufatruing unit in Bryan, Ohio, US.
  • 2005: The Company acquires ICN’s business in Hungary from Valent Pharma.
  • 2005: The Company acquires intellectual property and assets of Able Labs from US District Bankruptcy court in New Jersey.
  • 2008: The Company acquires Chattem Chemicals Inc, US.
  • 2010: The Company acquires controlling stake in Israel-based Taro Pharmaceuticals, USA to effectively double company’s US businesses.
  • 2012: The Company completes two more acquisitions in USA; Dusa Pharmaceuticals and the generic business of URL Pharmaceuticals.
  • 2014: The Company acquires Ranbaxy in a $4 billion landmark transaction to create world’s fifth largest specialty generic pharma company.
  • 2014: The Company acquires pharmalucence in USA.
  • 2015: The Company acquires GSK’s Opiates business in Australia
  • 2015: The Company acquires Insite Vision Inc. to strighthen branded ophthalmic portfolio in USA.
  • 2016: Sun Pharma acquires 14 brands from Novartis in Japan
  • 2016: Sun Pharma acquires Ocular Technologies, Sarl to strengthen branded ophthalmic portfolio
  • 2016: Sun Pharma acquires branded oncology product Odomzo (sonidegib) from Novartis for global markets
  • 2016: Sun Pharma acquires Biosintez to enhance presence in Russian market

Research & Manufacturing

  • 1983:Sun Pharma sets up compact manufacturing facility for tablets and capsules at Vapi, Gujarat
  • 1991: Sun Pharma establishes first research centre to create a base for strong product and process development
  • 1991: Ranbaxy establishes state-of-the-art manufacturing facility for Cephalosporins at Mohali, Punjab, India
  • 1995: Sun Pharma begins production at API manufacturing plant in Panoli, Gujarat, India.
  • 1997: Sun Pharma establishes new research facility in Mumbai, India
  • 1998: Sun Pharma begins operations at a new formulation unit in Silvassa, Gujarat, India
  • 2001: Sun Pharma commences production at new formulations unit in Dadra, India
  • 2004: Sun Pharma sets up new formulation unit in Jammu, India
  • 2004: Sun Pharma commissions first joint venture manufacturing unit in Dhaka, Bangladesh
  • 2015: Sun Pharma enters into research collaboration with Weizmann Institute of Science, Israel & Health Research Institute of Santiago, Spain for brain therapies
  • 2016: International Centre for Genetic Engineering and Biotechnology (ICGEB) & Sun Pharma sign an exclusive agreement to develop novel botanical drug for treatment of Dengue
  • 2017: Sun Pharma & National Institute of Virology (NIV), India sign agreement to fight Zika, Chikungunya and Dengue

Products & Innovations

  • 1987: Sun Pharma begins sale of products across India
  • 1988: Sun Pharma launches Monotrate and Angizem, first cardiology products that are sold till today
  • 1989: Sun Pharma introduces gastroenterology products in India
  • 1998: Sun Pharma acquires a basket of products from Natco Pharma
  • 2014: Sun Pharma and Merck & Co. Inc. enter into licensing agreement for Tildrakizumab (MK-3222)
  • 2016: Sun Pharma launches Imatinib Mesylate in USA
  • 2016: Sun Pharma launches first branded ophthalmic product, BromSite in USA
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.